Resistant and relapsing neuroblastoma: Improved response rate with a new multiagent regimen (OC-HDP) including high-dose cisplatinum

G. Dini, E. Lanino, D. Rogers

Research output: Contribution to journalArticlepeer-review

Abstract

From September 1984 to July 1985, 11 children from 6 months to 6 years of age were treated with a three-drug regimen (OC-HDP), including vincristine, cyclophosphamide, and cisplatinum 200 mg/m2 given as five dose-fractions over 5 days. Nine had resistant and two relapsed neuroblastoma. Nine children had previously been treated with cisplatinum at conventional doses; nine had not received cyclophosphamide and ten had not received vincristine. Nine of eleven patients had a good response to treatment; six are presently alive in continuous complete remission 11-23 months (median 13 months) after diagnosis. Toxicity was moderate: no child showed either severe myelotoxicity or clinical or laboratory evidence of nephrotoxicity. No child had clinically significant ototoxicity. In six children audiometry showed hearing loss for high frequencies after the third cycle of treatment. It is concluded that OC-HDP regimen could be considered as a first-line treatment for advanced neuroblastoma.

Original languageEnglish
Pages (from-to)1823
Number of pages1
JournalMedical and Pediatric Oncology
Volume15
Issue number1
Publication statusPublished - 1987

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Resistant and relapsing neuroblastoma: Improved response rate with a new multiagent regimen (OC-HDP) including high-dose cisplatinum'. Together they form a unique fingerprint.

Cite this